We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long‐term prognosis of fatty‐acid oxidation disorders in adults: Optimism despite the limited effective therapies available.
- Authors
Rouyer, Alice; Tard, Céline; Dessein, Anne‐Frédérique; Spinazzi, Marco; Bédat‐Millet, Anne‐Laure; Dimitri‐Boulos, Dalia; Nadaj‐Pakleza, Aleksandra; Chanson, Jean‐Baptiste; Nicolas, Guillaume; Douillard, Claire; Laforêt, Pascal
- Abstract
Introduction: Fatty‐acid oxidation disorders (FAODs) are recessive genetic diseases. Materials and methods: We report here clinical and paraclinical data from a retrospective study of 44 adults with muscular FAODs from six French reference centers for neuromuscular or metabolic diseases. Results: The study cohort consisted of 44 adult patients: 14 with carnitine palmitoyl transferase 2 deficiency (32%), nine with multiple acyl‐CoA deficiency (20%), 13 with very long‐chain acyl‐CoA dehydrogenase deficiency (30%), three with long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency (7%), and five with short‐chain acyl‐CoA dehydrogenase deficiency (11%). Disease onset occurred during childhood in the majority of patients (59%), with a mean age at onset of 15 years (range = 0.5–35) and a mean of 12.6 years (range = 0–58) from disease onset to diagnosis. The principal symptoms were acute muscle manifestations (rhabdomyolysis, exercise intolerance, myalgia), sometimes associated with permanent muscle weakness. Episodes of rhabdomyolysis were frequent (84%), with a mean creatinine kinase level of 68,958 U/L (range = 660–300,000). General metabolic complications were observed in 58% of patients, respiratory manifestations in 18% of cases, and cardiological manifestations in 9% of cases. Fasting acylcarnitine profile was used to orient genetic explorations in 65% of cases. After a mean follow‐up of 10 years, 33% of patients were asymptomatic and 56% continued to display symptoms after exercise. The frequency of rhabdomyolysis decreased after diagnosis in 64% of cases. Conclusion: A standardized register would complete this cohort description of muscular forms of FAODs with exhaustive data, making it possible to assess the efficacy of therapeutic protocols in real‐life conditions and during the long‐term follow‐up of patients.
- Subjects
CARNITINE palmitoyltransferase; MUSCLE weakness; NEUROMUSCULAR diseases; CARDIOLOGICAL manifestations of general diseases; GENETIC disorders; GLUCOSE-6-phosphate dehydrogenase deficiency
- Publication
European Journal of Neurology, 2024, Vol 31, Issue 2, p1
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/ene.16138